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Abstract 
Protein-protein interactions (PPI) are involved in vital cellular processes and are 
therefore associated to a growing number of diseases. But working with them as 
therapeutic targets comes with some major hurdles that require substantial mutations 
from our way to design to drugs on historical targets such as enzymes and G-Protein 
Coupled Receptor (GPCR). Among the numerous ways we could improve our 
methodologies to maximize the potential of developing new chemical entities on PPI 
targets, is the fundamental question of what type of compounds should we use to 
identify the first hits and among which chemical space should we navigate to optimize 
them to the drug candidate stage. In this review article, we cover different aspects on 
PPI but with the aim to gain some insights into the specific nature of the chemical space 
of PPI inhibitors. We describe the work of different groups to highlight such properties 
and discuss their respective approach. We finally discuss a case study in which we 
describe the properties of a set of 115 PPI inhibitors that we compare to a reference set 
of 1730 enzyme inhibitors. This case study highlights interesting properties such as the 
unfortunate price that still needs to be paid by PPI inhibitors in terms of molecular 
weight, hydrophobicity, and aromaticity in order to reach a critical level of activity. But 
it also shows that not all PPI targets are equivalent, and that some PPI targets can 
demonstrate a better druggability by illustrating the better drug likeness of their 
associated inhibitors. 
Abbreviation 
PPI   Protein-Protein Interaction 
iPPI   small molecule inhibitor of Protein-Protein Interaction 
RO5   Lipinski’s Rule of Five 
ADME/Tox  Absorption Distribution Metabolism Excretion/ Toxicity 
LE Ligand Efficiency: Gibbs Free Energy of binding/(number of heavy 
atoms) 
LEHA  Ligand Efficiency: pIC50/(number of heavy atoms) 
  LEHA = pIC50/(number of  heavy atom) 
LLE Lipophilic Efficiency 
LLE =  pIC50 - AlogP  
ΔASA   Solvent accessible surface area 
Introduction 
As the pharmaceutical industry and the academic system are under a dramatic pressure 
to offer more efficient and safer drugs to the patients on a growing number of diseases, 
there are urgent needs to boost pharmaceutical innovations (novelty of effectiveness), 
and developing new conceptual frameworks/methodological tools to assist the 
discovery of novel drugs. This may come, for instance, with the study of new 
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therapeutics targets. But it requires sufficient knowledge prior to embark to such 
expensive investigations. To this end, tremendous efforts in the clarification of the role 
of Protein-Protein Interactions (PPI) in the health and disease states are currently 
taking place. Indeed, PPI, by their implication in numerous cellular mechanisms are 
more and more linked to a growing number of diseases and therefore represent a 
remarkable pool of putative therapeutic targets. With an estimation ranging from 
130,000[1] to about 650,000[2] PPI in human, excluding trans-organism PPI (mainly 
important for infectious diseases), the number of potential targets is exceptional, 
although not all those PPI might represent a druggable target capable of binding a small 
molecular drug nor some might be relevant to pursue given their role in a particular 
biological pathway. Nevertheless, despite their potential at the biological level, PPI have 
been thought for many years to be undruggable[3] or too risky using low molecular 
weight molecules. The first reason involved the topological nature of their interface, 
assumed to be too large and/or too hydrophobic to be compatible with the 
physicochemical properties of most known small molecular drug candidates (these 
properties involve mainly molecular weight and octanol water partition coefficient most 
often reported as logP). The second reason is the nature of the chemical collections that 
are used presently in high throughput screening campaigns that were essentially 
designed for regular targets such as G-protein Coupled Receptors (GPCR), ion channels 
and enzymes. Yet, the growing number of success stories in the modulation of PPI with 
small molecules including peptido-mimetic and “regular” chemical compounds, allows 
now the scientific community to start gaining insight into the general properties that an 
inhibitor of PPI (iPPI) should possess, at least in the light of existing successful 
examples. This indeed represents valuable information about their associated chemical 
space and potential strategies to explore further this challenging class of novel 
therapeutic targets. 
In this review, we will describe our present knowledge of the iPPI chemical space and 
how we could derive in the near future new ways of both filtering and prioritizing 
chemical synthesis of putative iPPI with acceptable pharmacokinetic profiles. But before 
going further we should start by clarifying and explaining some keys concepts on PPI 
and the type of pharmacological modulation considered will be summarized in order to 
properly assess the corresponding physico-chemical profile of iPPI. 
Types of interaction 
PPI are highly heterogeneous and can be found in many forms. Indeed, depending 
whether they are obligate or non-obligate, permanent or transient, involved in weak or 
strong interactions, different topological, kinetic (kon, koff) and energetic profiles can be 
anticipated and therefore can have various consequences on the physico-chemical and 
pharmacological profiles of iPPI. The concentration in cells of both protein partners (or 
more if multimers) may also become prevalent and have different consequences on the 
pharmacological modulation one might want to achieve. 
One can also argue on the type of protein partners involved. Indeed, it is not unusual to 
consider as a PPI an interaction between a protease and its substrate or with some 
protein inhibitor (eg eglin C with different serine proteases). The debate could therefore 
be whether one should consider the catalytic site of a protease as the location of a true 
transient interaction with its substrate or as a site of chemical reaction intermediate 
(here tetrahedral intermediate) in which for a very short duration the two proteins are 
chemically bound to each other with evidently very different consequences in terms of 
binding profiles. In addition, there might be confusions about the meaning of protein-
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protein interactions. The type of interactions that we address here are true interaction 
in a sense that the interface zone involved does not overlap with a catalytic site or with 
pocket known to bind a small compound. For instance, some GPCRs can bind a number 
of external and endogenous compounds in some well known binding cavities, some of 
these binders are small ligands/substrates, others are peptides or else entire proteins 
but these binding pockets have indeed evolved to bind large and small ligands but do 
not fit into the type of interactions that we are investigating here. Again, if we consider 
BPTI, this protein binds and blocks the catalytic site of a serine protease, compounds 
that will block this interaction by interacting with the serine protease active site can not 
be considered a true PPI inhibitors as this pocket has also evolved to bind small ligands 
and as such there will be little to learn that we already know in term of chemistry and 
chemical space specificity. 
Properties of the interface 
Various studies have described the topological properties of PPI at the interface[4, 5], 
and the purpose of this review is not to go through all of them but rather to cite some 
and attempt to extract what could be appropriate in terms of anticipated physico-
chemical properties for an ideal iPPI. In an influential study, Jones and Thornton by 
analyzing a set of 59 complexes found that the solvent accessible surface area (ΔASA) 
spans from 368 Å2 to 4746 Å2 in homodimers and from 639 Å2 to 3228 Å2 in 
heterocomplexes[6]. Yet, ten of the PPI within that study were based on 
enzyme/inhibitor complexes, with an average ΔASA of 785 Å2 among the smallest of the 
full dataset. Nevertheless, this gives a conceptual idea of the size an iPPI might need to 
reach to mimic the presence of the native partner to prevent its interaction. Fortunately, 
the seminal work of Wells[7] using alanine scanning has highlighted the presence of key 
residues at the interface on which resides most of the binding energy. This confirmed 
that only part of the interaction patch really contributes to the partners’ binding such 
that, as long as the iPPI is capable of disrupting those hot spots, the modulation is at 
least theoretically achievable. The growing number of success stories, and especially the 
work achieved by the fragment-based community has supported this observation on 
various cases. 
The contributions of various residues at the interface can also provide valuable 
information that could be translated into chemical properties of iPPI. Several studies 
have attempted to assess the over-representation of key amino acids within protein 
interfaces. These studies have for example highlighted the importance of Trp/Met/Phe 
clusters within hotspots regardless of the type of PPI considered[8] or more specifically 
the presence of Phe, Trp, Leu and Arg in α-helix mediated interaction[9].  Other 
studies[10] have analyzed aromatic-aromatic interactions between protein partners and 
described geometrical distribution and orientation of the aromatic rings in place. Finally, 
some studies have attempted to overlap the protein binding sites with small molecules 
within families of structures including PPI[11] and others start to propose methods and 
tools to predict what interface could be adapted for low molecular weight compound 
modulation[12]. The combination of this information could be used in some cases to 
derive physico-chemical properties matching both those of the corresponding residues 
and more generally those of the associated binding pockets. 
Orthosteric versus allosteric modulation 
Besides the interface and type of interaction, the type of modulation is also to be 
considered. Inhibitors can be for instance direct/orthosteric inhibitors binding 
essentially at the interface between two proteins (very few small organic compounds 
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orally available are known at this time) or can be allosteric inhibitors, thereby binding 
at, near or far away from the interface in cavities with recognition characteristics that 
could be highly similar to enzyme active sites. It would seem logical to explore and 
attempt to rationalize the properties of the direct protein-protein inhibitors (they also 
may act via small structural changes) because the chemistry of these ones is likely to be 
novel as the compounds have to bind to surfaces that have not evolved to bind small 
molecules. Also allosteric compounds have been used for many years but the mechanism 
of action has often been found retrospectively because of the complexity of the 
mechanisms involved. Thus, although allosteric inhibitors are interesting from an 
energetic standpoint, for their selectivity…etc, this is not the type of compounds that we 
will be dealing with in this review to explore novel regions of the chemical space (i.e., 
these regions might be already known or the complexity of the molecular events taking 
place impede, at our present level of knowledge, rationalization). For instance, 
maraviroc (a nonpeptidic, small molecule human immunodeficiency virus type 1 (HIV-1) 
entry inhibitor) that binds to the CC chemokine receptor 5 (CCR5), a G-protein coupled 
receptor, prevents the binding of the chemokine CCL3 and the viral envelope 
glycoprotein gp120 by an allosteric mechanism would not be considered as a true iPPI 
in our case study as it inhibits the interaction by an allosteric mecamism. 
Leap into the iPPI chemical space 
Seminal works 
Historically, a vast number of studies have been successfully used to rationally design 
iPPI mostly around privileged structures including peptido-mimetic compounds or 
specific scaffolds[13-22]. Here we will give a global overview of the various profiling 
that have been carried out on existing iPPI and present a synthetic depiction of the 
generic physico-chemical profile of these small molecules.  
Besides the legitimate wish to derive physico-chemical properties for iPPI from the 
topological properties of protein interfaces, a major leap can be undertaken into the 
chemical space of iPPI by analyzing the successful examples of iPPI themselves. Various 
initiatives have been undertaken to establish some general trends on the chemical space 
of iPPI, both to describe its characteristics and to underpin its paradigm shift with 
respect to those of commercial chemical libraries. 
By analyzing 19 iPPI from the literature active on 12 different PPI targets using a 
principal component analysis with three molecular descriptors (LogP, Molecular Weight 
and Polar Surface Area), Pagliaro et al showed that their chemical space (at least 
described by those descriptors) did not overlap those of three chemical vendors. Indeed, 
the inhibitors of only 4 targets out of 12 (Bcl-xL/Bak, MDM2/p53, NGF/p75, and 
ICAM/LFA) were covered by those commercial collections. They also showed that only 8 
out of 19 iPPI could survive Lipinski’s RO5 (see below).  
In an other study Wells and McClendon have estimated the ligand efficiency of a dozen 
of iPPI to be around 0.24 kcal/mol compared to those of protease inhibitors (0.25-0.35 
kcal/mol) or kinase inhibitors (0.30-0.40 kcal/mol). This would bring the molecular 
weight of an iPPI having a 10nM KD to 645 Da, therefore representing a first violation to 
the Lipinski’s RO5. 
Several studies have highlighted general and qualitative trends for iPPI. Particularly, 
reviews from Berg, Fry, and Wilson described iPPI with higher molecular, higher 
hydrophobicity, higher number of rings, higher aromaticity[13-17]. 
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The road to a rationalization of the iPPI chemical space 
With the final goal of improving the poor hit rates usually obtained during the HTS 
campaigns, several studies have been performed either to propose collections of 
crystallized iPPI or statistical models able to partially rationalize the global chemical 
space of iPPI. These endeavors should indeed assist in the selection or synthesis and 
prioritization of compounds to be screened and thus contribute to enrich the compound 
libraries in putative protein-protein interface binders. 
Concerning the former type of approaches, two different groups have gathered into 
online databases co-crystallized iPPI. First of this kind, the Timbal database[18] contains 
89 iPPI with pharmacological data on 19 PPI targets. Among those, 41 iPPI are co-
crystallized, which represents a cumulated number of 10 PPI targets. Similarly, the 2P2I 
database[19] collects 42 crystallized iPPI with data on both the apo- and the holo-
structures on 10 different PPI targets. 
Beyond providing to the PPI community collections of iPPI taken from the literature, 
other initiatives have attempted to propose some rationalization of the iPPI chemical 
space. The work of Neugebauer[20] used machine-learning techniques on a small set of 
25 iPPI and 1135 FDA-approved drugs, as non-iPPI to try to characterize a physico-
chemical profile specific of iPPI. They showed in the context of their dataset, that the 
combination within a decision tree of very few descriptors including SHP2 (known as a 
shape descriptors introduced by Randic), and the number of ester functions was capable 
of producing a focused collection with several fold enrichments of inhibitors of protein-
protein interactions. Morelli et al. also using some statistical techniques on 39 iPPI from 
the 2P2I database data have recently proposed a set of thresholds for some commonly 
used physico-chemical properties in drug development[21]. Their data are 
characterized by averages values for the molecular weight, AlogP, number of rings and 
number of Hydrogen bond acceptors of 547 ± 154 Da, 3.99 ± 2.37, 4.44 ± 1.02, 6.62 ± 
2.60, respectively. 
Recently, our group used a complementary approach[22, 23] to further characterize the 
physico-chemical profile of iPPI. A set of 66 iPPI “ADME/Tox compatible” (at least after 
some in silico predictions), and diverse chemically, was fed to a statistical analysis along 
with a negative dataset of 557 regular drugs that resulted from the same filtering and 
diversity protocol. The statistical analysis was designed to highlight discriminative 
descriptors capable of separating the global iPPI population from the regular drug 
population. Common descriptors such as MW, AlogP, TPSA, nb of rings, etc, were also 
inspected to collectively provide a full evaluation of the physico-chemical profile of iPPI 
and therefore gave the first quantified characterization of their chemical space. The 
main results emphasized an average MW of 421 Da for iPPI versus 341 Da for regular 
drugs, and an average AlogP of 3.58 versus 2.61. Those results also showed that the 
number of rings (=4), benzene-like rings (=2), and aromatic bonds (=16) are 
significantly higher in iPPI than in regular drugs. Finally and importantly, the statistical 
model, PPIHitProfiler, that was constructed within those two studies, namely a two-
descriptor decision tree (using RDF070m, and unsaturation index) demonstrated that 
the combination of a specific molecular shape and a critical number of 17 multiple bonds 
is determinant to maximize the iPPI potential of a compound. The model was further 
validated on experimental screening data taken from PubChem BioAssay on a cumulated 
number of 500 000 tested compounds across 11 assays. The conclusions of this work 
were further used to prepare a chemical collection in a recent study that led to the 
identification of small compound that inhibit the von Willebrand Factor (VWF) A1 - 
glycoprotein (GP) Ibα interaction[24]. 
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Case Study 
In order to propose an update on the major physico-chemical properties of iPPI, we have 
assembled a chemically diverse set of 115 iPPI that are active on 4 of the most widely 
studied PPI in the literature, namely the p53/MDM2, Xiap/smac, Bcl-2 family/Bak, and 
ICAM-1/LFA-1 interactions (Figure 1, left panel). As a reference dataset, we have also 
considered a representative pool of 1730 chemically diverse inhibitors active on the 
most widely studied enzymes including some kinases, all taken from the binding 
database[25] (www.bindingDB.org) along with their binding affinities (Figure 1, right 
panel). Compounds from the BindingDB are a mix of hits, optimized compounds (lead), 
and some times drugs depending on the study and the degree of validation of the target. 
In this reference dataset, the 1730 compounds were taken from an initial set of 46000 
active compounds which was submitted to fingerprint-based sampling (ward clustering) 
to ensure chemical diversity. A series of 24 interpretable molecular descriptors (Table 
1) such as molecular weight, AlogP, number of sp3 carbon, number of rings, etc… was 
calculated on the two datasets for estimating the relative characteristics of their 
respective chemical space and the major properties associated with it. JChem Base was 
used to generate de novo conformations of the compounds and calculate the descriptors, 
JChem 5.7, 2011, ChemAxon (www.chemaxon.com). 
 
 
Figure 1: Distribution of iPPI and enzyme inhibitors across their corresponding targets 
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Table 1 
N° Descriptor Code Descriptor Name N° Descriptor Code Descriptor Name 
1 MW Molecular Weight 13 nCsp3 Nb of sp3 Carbon 
2 nAT Nb of atoms 14 nCIC Nb of rings 
3 nSK Nb of heavy atoms 15 nBnz Nb of benzene-like rings 
4 nBT Nb of bonds 16 ARR Aromatic ratio 
5 RBN Nb of rotatable bonds 17 RDF070m 
Radial Distribution Function 
at 7 Angstroms weighted by 
atomic mass 
6 RBF 
Fraction of rotatable 
bonds 
18 nCar Nb of aromatic carbon 
7 nDB Nb of double bonds 19 nHDon Nb of H bond donor 
8 nAB Nb of aromatic bonds 20 nHAcc Nb of H-bond acceptor 
9 nC Nb of Carbon 21 Ui Unsaturation index 
10 nN Nb of Nitrogen 22 AMR Molecular refractivity 
11 nO Nb of Oxygen 23 TPSA.Tot. Topological surface area 
12 nX Nb of Halogen 24 ALOGP logP 
Visualizing the iPPI chemical space 
To visualize the chemical space corresponding to those two datasets, we ran a principal 
component analysis (PCA) using the 24 molecular descriptors listed above on the 
merged datasets (iPPI + enzyme inhibitors)  (Figure 2). Data were scaled to unit 
variance. The respective positions in chemical space of iPPI (colors dots) on one hand 
and of the enzyme inhibitors (black dots) on the other hand, within the individual map 
(top panel), show that there is a slight shift between the two population distribution, the 
iPPI population being out centered toward the bottom right side of the map. An 
examination of the variable map (bottom panel) and the descriptors associated to the 
two first axis of the PCA, that represent more than 60% of the total variance, permit to 
identify the main physico-chemical properties’ discrepancies responsible for this shift. 
Indeed, the first axis is positively correlated to the size of the compounds (e.g molecular 
weight, number of heavy atoms, number of carbon, etc). The second axis is clearly 
negatively correlated to the aromatic ratio i.e to the proportion of aromatic atoms in the 
compounds. This collectively means that iPPI tend to be heavier and more aromatic than 
enzyme inhibitors, and that this seems to be the most prevalent characteristics in terms 
of global variance. But it can also be observed, using the individual map, that not all iPPI 
are characterized equally by this tendency, depending on the compound but also on the 
PPI target one considers. For example, MDM2 compounds (cyan) seem to be among the 
most aromatic iPPI (bottom of the map) while Xiap compounds (blue) are not as 
aromatic (upper in the map). Also, one can easily see that Bcl-2 inhibitors have very 
different positions along the first axis and that some of the Bcl-2 compounds (red) are 
 8 
shifted right because of their significantly higher size, while some of the LFA compounds 
(green) are quite similar in size with enzyme inhibitors.  
The third axis of the PCA, when combined with the two first, represents 73% of the 
cumulated variance and mostly correlates with the number of sp3 carbon and TPSA. 
Interestingly, the difference of mean values for those two descriptors was not significant 
between iPPI and enzyme inhibitors. 
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Figure 2: Principal Component Analysis. Individual map (top panel) with enzyme inhibitor in black, Bcl-2 
inhibitors in red, MDM2 inhibitors in cyan, LFA inhibitors in green, and Xiap inhibitors in blue. Variable or 
descriptor map (bottom panel). For both panels the two first axis of the PCA are represented covering 
more than 60% of the total variance. 
iPPI versus ADME/tox properties 
One very important aspect when developing drug candidates is the control of some key 
properties such as the molecular weight and the logP to avoid undesired behavior like 
promiscuous binding, poor solubility, or toxicity[26]. This becomes particularly true 
when dealing with compounds aiming at being administrated orally. To this end, the 
work of Lipinski and the so-called Rule of 5 (RO5) is well known [27]. The RO5 states 
that drugs that are designed for oral administration should have a molecular weight 
below 500 Da, a logP below 5, a number of Hydrogen bond acceptors below 10, and a 
number of Hydrogen bond donors below 5. Although the drug design community does 
not always fully agree with this guideline and physico-chemical thresholds, it is however 
widely used. Previous studies such as the one mentioned above, carried out by Pagliaro, 
found that among 19 iPPI identified from the literature only 8 could survive the RO5. 
Although it is not clear from their paper whether they tolerated two, one or no violation 
to the rule, it is interesting to apply the RO5 on this bigger representative sample of 115 
iPPI and compare the results with enzyme inhibitors. The figure below (Figure 3) 
shows that if one applies the RO5 with no violation tolerated, more than two third of the 
iPPI are rejected (69%). This would evidently make High Throughput Screening 
campaigns less inclined to identify new compounds capable of modulating PPI targets. If 
one violation is tolerated, which is most of the time the case when using the RO5, the 
situation is clearly not as dramatic with this time almost two third (65%) of the iPPI 
being accepted although it is not as high as for enzyme inhibitors (84%). In the case of 
two violations tolerated the situation for iPPI (91% accepted) is similar to enzyme 
inhibitors (99% accepted).  
 
 
Figure 3: RO5 rule versus iPPI and enzyme inhibitors 
 
 10 
We then took into consideration the individual physico-chemical properties concerned 
by the RO5 and also by the Veber rule[28] (TPSA < 140 Å2 and Number of Rotatable 
Bonds (RBN) < 10) using univariate distributions combining histograms and box plots 
(Figure 4). Those plots can show the most discriminative properties between the 
enzyme inhibitors and iPPI. As seen on the figure below, the mean value for AlogP on 
iPPI is 5.15, while it is 3.5 for enzyme inhibitors with a statistically significant difference 
(p-value << 0.05). The same is true with the molecular weight with a mean value of 496 
Da for iPPI and of 388 Da for enzyme inhibitors with again a statistically significant 
difference (p-value << 0.05). But the other properties are either similar (nHDon, nHAcc, 
TPSA) or not statistically very different (RBN).  
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Figure 4: Double histograms and box plots for the RO5 and Veber descriptors. The enzyme inhibitors 
distributions are shown in green, and the iPPI are shown in red. 
 
This describes a very important aspect of the propensity of iPPI for NOT being orally 
bioavailable, at least in the scope of the Lipinski-derived estimation of oral routing. This 
means that the main reason for not respecting the RO5 and therefore for having a poor 
propensity for being orally bioavailable is only due to too high molecular weight and to 
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too high logP and apparently not to the other important physico-chemical properties 
involved in the RO5 and Veber rules.  
This is confirmed by the figure below (Figure 5), which shows boxplot figures of those 
RO5 and Veber descriptors per PPI target along with their threshold as horizontal black 
lines. One can see for every PPI target, iPPI have a mean value for the molecular weight 
centered on about 500 Da, while there seems to be a very specific profile for Xiap 
compounds that are clearly not as hydrophobic as confirmed by their reduced aromatic 
character (mentioned above in the PCA individual map). For the other descriptors, there 
is clearly no problem in terms of RO5 or Veber rule violations even for some of the large 
compounds of the Bcl-2 family. 
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Figure 5: Individual vertical boxplot for iPPI on the 4 PPI targets using the RO5 and Veber descriptors. On 
each vertical boxplot is represented the corresponding threshold as horizontal black line, e.g 500 Da for 
MW in the RO5.  
 
In the biplot view below (Figure 6) which combines molecular weight and AlogP values 
for iPPI per PPI target one can see that most of the iPPI do not respect one of those two 
descriptors and some none of them. This also means that because more than two third of 
iPPI respect the RO5 with one violation there must be some balance mechanism that do 
exist preventing most of iPPI from being concomitantly over the molecular weight and 
logP thresholds. The MW-AlogP biplot also shows that not all PPI targets are equally 
represented by their iPPI. Indeed, the Xiap compounds (blue) are all below the AlogP 
threshold of 5 with most of the time a moderate molecular weight. 
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Figure 6: MW-AlogP biplot for the iPPI on the 4 PPI targets. Bcl-2 inhibitors in red, MDM2 inhibitors in 
cyan, LFA inhibitors in green, and Xiap inhibitors in blue. 
 
A similar biplot figure (Figure 7) combining AlogP and TPSA allows one to consider the 
3-75 rule that is usually applied to evaluate compound toxicity[29]. This rule stipulates 
that compounds with a logP below 3 and a TPSA or PSA above 75 Å2 have better 
propensity for not being toxic. As can be seen on this biplot very few iPPI are in good 
agreement with this rule, and most of them are Xiap compounds (blue). Two of them are 
LFA/ICAM inhibitors (green). But this studies also shows that the most problematic 
compounds in terms of toxicity are in the top-left corner of the biplot (logP > 3 and TPSA 
< 75 Å2), and that compounds in the top right corner (logP > 3 and TPSA > 75 Å2) have 
almost the same toxicity profile than those of the bottom right corner (logP < 3 and 
TPSA > 75 Å2) at least when considering all drugs regardless of their human serum 
albumin binding profile. Such that in the case of iPPI a fair amount of compounds is not 
associated to any toxicity profiles at least in the scope of this dataset. 
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Figure 7: 3-75 Rule for the iPPI on the 4 PPI targets. Bcl-2 inhibitors in red, MDM2 inhibitors in cyan, LFA 
inhibitors in green, and Xiap inhibitors in blue. 
 
iPPI versus aromaticity 
As mentioned in the introduction, various studies have described the importance of 
aromaticity when it comes to designing iPPI, phenyl moieties are over represented, 
fragment such as biphenyl are known for years to be a good start to some extent when 
initiating a chemistry project on PPI targets. The best example is the identification of 
ABT-737 on Bcl-2 using fragment-based approach with, among the first chemical 
fragment probe, a biphenyl group that was latter on used to design the full 
compound[30]. In our previous work we demonstrated the importance of multiple 
bonds for iPPI through the identification of the unsaturation index descriptor (Ui) to 
which, most of all, the number of aromatic bonds is contributing. Here, we have used a 
combination of several univariate distributions to confirm, on this new and more 
populated dataset, the importance of the Ui descriptor to discriminate between iPPI and 
none iPPI compounds (here enzyme inhibitors) and therefore the importance of 
aromatic bonds. As can be seen on figure 8, Ui and the number of aromatic bonds (nAB) 
have statistically significant different mean values between iPPI and enzyme inhibitors, 
while the number of double bonds (nDB), which also contributes to Ui, has not. The 
figure also shows that the significant higher number of rings (nCIC) among iPPI is 
certainly due to a higher number of benzene-like rings (nBnz) confirming the prevalence 
of phenyl groups among iPPI. 
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The vertical boxplot panel for Ui describing PPI target individually shows that the 
number of multiple bonds is particularly high for MDM2 and Bcl-2 compounds, while it 
is moderate for LFA and Xiap compounds. Aromaticity and therefore hydrophobicity 
seems to be a price to pay to reach a sufficient level of potency for the two former 
targets. 
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Figure 8: Double histograms and boxplot for the enzyme inhibitors (green) and iPPI (red) using the bond 
valence and rings descriptors.  
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iPPI versus chemical complexity 
A characteristic that is now commonly inspected within chemical compounds is their 
level of structural complexity. Various ways exist to evaluate this complexity; here we 
have considered two of them, the ratio of sp3 carbons and the number of stereo centers. 
It is clear from the figure below (Figure 9), that iPPI active on target Xiap/smac have a 
specific profile with respect to other PPI targets and to enzymes. It is non-only 
characterized by a significantly higher sp3 carbon ratio but also by a higher number of 
chiral centers. This is evidently in total agreement with the less pronounced aromatic 
character of the iPPI on Xiap compared to iPPI on Bcl-2 and MDM2 (as highlight within 
the principal component analysis paragraph above), which are characterized by a higher 
proportion of sp2 atoms. This, combined to a significant higher ratio of heteroatoms 
(data not shown) could explain the lower logP found for iPPI on Xiap.  
 
 
 
 
 
Figure 9: Structure complexity of iPPI versus enzyme inhibitors. The figure shows the sp3 carbon ratio 
(top panel) and the number chiral centers (bottom panel). 
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iPPI versus molecular shape 
Molecular shape is known to be key for binding regardless of the targets and help to 
maximize the surface complementarities between ligand and protein. Specific ligand 
shapes have been proposed to be appropriate in the binding of a variety of proteins [31, 
32]. In the field of PPI, Neugebauer et al. identified the SHP2 descriptor as important for 
iPPI potential. Yet, this descriptor is known for years as a shape descriptor. Our group 
has also shown the importance of molecular shape for iPPI but quantitatively. In our 
previous work we identified the molecular shape descriptor RDF070m (Radial 
Distribution Function descriptor) as specific to iPPI. On this new dataset, univariate 
distributions (Figure 10) confirm the discriminative character of RDF070m toward iPPI 
and highlight the more important prevalence of specific shape for the MDM2 and Bcl-2 
targets than for the LFA and Xiap targets due to different distributions. It seems that 
ramified structures and therefore more radially distributed atoms such as those found 
for the MDM2 compounds are favored to address simultaneously the different 
subpockets of MDM2. This is confirmed by the work of Fuller et al[3] which showed that 
PPI pockets, as opposed to regular target pockets, have several sub-pockets rather than 
one large well defined and mostly continuous pocket. 
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Figure 10: Double histogram and boxplot for enzyme inhibitors (green) and iPPI (red) using the molecular 
shape descriptor RDF070m (top panel). Vertical boxplot (bottom panel) per PPI target showing the 
threshold described in a previous study (13.15). 
 
Principal moments of inertia can also be used to evaluate the molecular shape of 
compounds. We used the combinations of the three principal moments of inertia to 
evaluate the global shape of the compounds in our two datasets iPPI + enzyme 
inhibitors. The three principal moments of inertia were calculated using PipelinePilot 
7.5, and were normalized such as to respectively divide the X and Y components by the Z 
component which had for consequence this triangular plot with each summit 
corresponding to an extreme shape. We then plotted them such as to distinguish rod- 
(top left corner), pancake- (bottom center), and sphere-like (top right corner) 
compounds as shown in the figure below (Figure 11)[33]. Moreover, in order to 
determine rod-, pancake- and sphere-like zones, we determined the equations of each 
summit’s bisection. Using those equations we were in the position to determine a simple 
counting of the compounds for each zone having an inclination for the 3 extreme types 
of shape. In the top left panel, one can see both the enzyme inhibitors (black) and iPPI 
(red). It is clear from this panel that most of the enzyme inhibitors tend to occupy the 
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rod-like region. This is confirmed by the stacked histograms from the bottom panel of 
Figure 11, which shows the distribution of the compound shapes per target type, among 
the 3 extreme shapes. Indeed, 81% of enzyme inhibitors have a rod-like shape for 
globally only 67% among iPPI. On the top right panel, the same representation with only 
iPPI but colored by PPI target shows that there seems to be a more equal distribution 
between the rod-like region and the pancake-like region with much fewer compounds 
having a sphere-like shape inclination. But interestingly, the few examples of 
compounds with a sphere-like shape are all MDM2 compounds, which is confirmed by 
the higher average value of RDF070m for this PPI target. Interestingly, the bottom panel 
shows that LFA and Xiap inhibitors have very similar profiles in terms of molecular 
shape distributions while most of the Bcl-2 inhibitors have a rod-like shape (86%) even 
greater in proportion than enzyme inhibitor. One might argue it is due to the topology of 
the Bcl-2 binding pocket, deep and extended, which receives a α-helix from the BH3 
domain of its partners that is about 20-amino acid long.  
 
 
 
 
 
Figure 11: Principal Moments of Inertia represented as a 2D plot. The triangle plots represent the global 
shape of the compounds sphere-like (yellow zone), pancake-like (blue-zone), and rod-like shape (green 
zone). Left panel shows both enzyme inhibitor (black) and iPPI (red). Right panel shows iPPI colored by 
PPI targets, Bcl-2 inhibitors in red, MDM2 inhibitors in cyan, LFA inhibitors in green, and Xiap inhibitors in 
blue. 
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iPPI versus Potency 
We have then analyzed the potency of those 115 iPPI versus enzyme compounds using 
activity bins of pIC50 as in the figure below (Figure 12). Cumulated proportions (left 
panel) show that only 6% of iPPI have pIC50 above 8 and 26% above 7, while 16% of 
enzyme inhibitors have pIC50 above 8 and 37% above 7. If the RO5 is applied to the 
datasets with one tolerated-violation, a closer look at the compounds that passed the 
RO5 (central panel) highlights identical proportions of compounds among the different 
activity bins for the enzyme inhibitors (16%, 21%, 25%, 38%). The same is not true with 
iPPI for which the pIC50-above-8 bin drops to 4% and the cumulated pIC50-above-7 bin 
drops to 19%. But the most striking results are obtained when considering the 
subpopulations that did not pass the RO5 (right panel). In that configuration, the 
proportion among bins is still similar for enzyme inhibitors, but changes dramatically 
for iPPI with a cumulated proportion of 46% of iPPI with a pIC50 above 7. This means 
that most of the most active compounds do not respect the RO5, which highlight the 
hydrophobic and molecular weight price that still needs to be paid in order to increase 
potency to the namomolar range. 
 
      
Figure 12: Normalized histograms of pIC50 bins comparing potency for enzyme inhibitors and iPPI in the 
context of the RO5. 
 
An examination of the ligand efficiency (LEHA) and lipophilic efficiency (LLE) using a 
biplot like the figure below confirmed that observation. When considering LE (Ligand 
Efficiency), for which the Gibbs free energy of binding is used, one can consider that 
value of 0.30 kcal/mol/heavy atom is desirable to obtain oral drug candidates[34]. As 
LEHA is unitless and around 0.73 times the LE value [35], this brings this druglikeness 
threshold using LEHA value to 0.22. Conversely, average LLE values for oral drugs are in 
the range 5-7[26]. The biplot figure (left panel) of LEHA (x-axis) and LLE (y-axis) shows 
that most of iPPI (red dots) are in the bottom left corner corresponding to poorer values 
of LEHA and LLE, whereas a wide proportion of enzyme inhibitors (black dots) occupy 
more favored regions for further optimizations (Figure 13). The right panel similarly 
shows the detail of efficiencies per PPI target. One can see that most of the iPPI 
respecting this efficiency profile are Xiap/smac and ICAM/LFA compounds. 
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Figure 13: Ligand efficiencies (LEHA, x-axis) and lipophilic efficiencies (LLE, y-axis). Top panel shows both 
enzyme inhibitors (black) and iPPI (red). Bottom panel shows iPPI colored by PPI targets, Bcl-2 inhibitors 
in black, MDM2 inhibitors in green, LFA inhibitors in cyan, and Xiap inhibitors in red. 
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iPPI versus PAINS 
An important aspect when dealing with active compounds during HTS binding assays is 
to ensure the screening is not revealing false positive compounds that could mislead 
chemists and biologists in the wrong direction. To this end, the work of Baell on Pan 
Assay INterference compounds - PAINS - is of particular importance to flag compounds 
containing fragments that are known to contribute to false positives in a wide range of 
biochemical assays[36]. Three sets of fragments were identified by Baell A, B, and C, A 
being the set of the most predominantly observed fragment-associated false positives. 
Using the program FAFDrugs2[37], we detected the PAINS corresponding to A, B, and C 
subsets in our two datasets. Figure 14 shows all the PAINS that are present within iPPI 
for the three subsets of PAINS fragments and the proportions of those PAINS for each 
PPI target and for enzymes. PPI inhibitors have a cumulated proportions of PAINS equal 
to 23% while it is only 5% for enzyme inhibitors, but the proportion of A-PAINS 
(fragments from subset A), which are again the most often observed PAINS, is similar 
(3%) for both iPPI and enzyme inhibitors. Interestingly, Xiap and LFA compounds have 
no PAINS at all. The most often present types of PAINS for iPPI are therefore for subsets 
B and C, and more specifically catechol_A for BCL-2 inhibitors (91% of B-PAINS), and 
anil_NH_alk_B for MDM2 inhibitors (100% of C-PAINS). So, not all PAINS from those 
subsets B and C are equally highlighted. The case of catechol_A is particularily 
interesting because it is present in a wide variety of BCL-2 inhibitors including gossypol 
derivatives among which some are in clinical trial in human (e.g AT101). So, information 
about PAINS associated compounds must be known but should be interpreted with 
caution.  
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Figure 14: Levels of PAINS on the datasets. (Top panel) Proportions of compounds flagged as PAINS for 
each target type and for the three types of PAINS; A, B, and C. (Bottom panel) Pie chart showing the PAINS 
fragments among iPPI. 
 
 
 
Conclusion 
Designing or identifying iPPI is known to be a difficult task. ADME considerations will 
also have to be taken into account at some point in the development if one wishes to go 
beyond chemical biology projects or proof of concepts. The examination of success 
stories can be used to rationalize the properties of existing iPPI and learn how to 
maximize the chances of success. Closer look at existing examples are necessary because 
they demonstrate major trends in the design and some balance that need to be found to 
reduce failure. The present case study analysis demonstrates that we have a long way to 
go in order to propose more drug/lead-like compound as iPPI because the major 
tendency is still to increase the hydrophobicity, the aromaticity, and the molecular 
weight of these compounds to maximize potency, but to levels that might not permit 
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further optimization (by contrast to new trends in enzyme inhibitor design). Indeed, 
already at the hit stage, iPPIs display properties that suggest higher risk of promiscuous 
binding or even toxicity. Yet, among the presented examples, some compounds have 
acceptable properties and some targets e.g Xiap seem to be exempted from the 
hydrophobic and weight prices to pay for potency and efficacy.  Lessons must be learnt 
from those examples both for iPPI drug-likeness and protein druggability or 
ligandability, which is the capacity of a protein to bind a small compound, in order to 
develop novel drug candidates for this new class of challenging targets. This opens the 
way of good practice both in terms of iPPI design but also in terms of PPI target 
categorization and the determination what type of PPI target must be prioritized[38]. To 
this end, a major leap must be taken toward a better comprehension of the different PPI 
categories. Must this categorization be pocket-driven, binder-driven (α-helix-, β-turn-, or 
β-sheet-mediated PPI), or compound-driven? And most of all to which category 
correspond both PPI ligandability and PPI druggability? Most likely, this learning phase 
will allow the scientific community to explore and to design more ADMET-friendly 
compound collections dedicated to the direct inhibition of protein-protein interactions 
within the next few years. 
 
References 
 
 
 
[1] Venkatesan K, Rual JF, Vazquez A, Stelzl U, Lemmens I, Hirozane-Kishikawa T, 
Hao T, Zenkner M, Xin X, Goh KI, Yildirim MA, Simonis N, Heinzmann K, Gebreab 
F, Sahalie JM, Cevik S, Simon C, de Smet AS, Dann E, Smolyar A, Vinayagam A, Yu 
H, Szeto D, Borick H, Dricot A, Klitgord N, Murray RR, Lin C, Lalowski M, Timm J, 
Rau K, Boone C, Braun P, Cusick ME, Roth FP, Hill DE, Tavernier J, Wanker EE, 
Barabasi AL, Vidal M. An empirical framework for binary interactome mapping. 
Nat Methods, 2009; 6: 83-90. 
[2] Stumpf MPH, Thorne T, de Silva E, Stewart R, An HJ, Lappe M, Wiuf C. Estimating 
the size of the human interactome. Proceedings of the National Academy of 
Sciences, 2008; 105: 6959-6964. 
[3] Fuller JC, Burgoyne NJ, Jackson RM. Predicting druggable binding sites at the 
protein-protein interface. Drug discovery today, 2009; 14: 155-161. 
[4] Perkins JR, Diboun I, Dessailly BH, Lees JG, Orengo C. Transient protein-protein 
interactions: structural, functional, and network properties. Structure (London, 
England : 1993), 2010; 18: 1233-1243. 
[5] Nooren IMA, Thornton JM. Diversity of protein-protein interactions. The EMBO 
journal, 2003; 22: 3486-3492. 
[6] Jones S, Thornton JM. Principles of protein-protein interactions. Proceedings of 
the National Academy of Sciences of the United States of America, 1996; 93: 13-
20. 
[7] Clackson T, Wells JA. A hot spot of binding energy in a hormone-receptor 
interface. Science, 1995; 267: 383-386. 
[8] Ma B, Nussinov R. Trp/Met/Phe hot spots in protein-protein interactions: 
potential targets in drug design. Current topics in medicinal chemistry, 2007; 7: 
999-1005. 
 30 
[9] Bullock BN, Jochim AL, Arora PS. Assessing helical protein interfaces for inhibitor 
design. J Am Chem Soc, 2011; 133: 14220-3. 
[10] Lanzarotti E, Biekofsky RR, Estrin DoA, Marti MA, Turjanski AnG. Aromatic-
aromatic interactions in proteins: beyond the dimer. Journal of Chemical 
Information and Modeling, 2011; 51: 1623-1633. 
[11] Davis FP, Sali A. The overlap of small molecule and protein binding sites within 
families of protein structures. PLoS computational biology, 2010; 6: e1000668. 
[12] Kozakov D, Hall DR, Chuang GY, Cencic R, Brenke R, Grove LE, Beglov D, Pelletier 
J, Whitty A, Vajda S. Structural conservation of druggable hot spots in protein-
protein interfaces. Proc Natl Acad Sci U S A, 2011; 108: 13528-33. 
[13] Berg T. Small-molecule inhibitors of protein-protein interactions. Curr Opin Drug 
Discov Devel, 2008; 11: 666-74. 
[14] Fry DC. Drug-like inhibitors of protein-protein interactions: a structural 
examination of effective protein mimicry. Curr Protein Pept Sci, 2008; 9: 240-7. 
[15] Fry DC. Protein-protein interactions as targets for small molecule drug discovery. 
Biopolymers, 2006; 84: 535-552. 
[16] Wilson AJ. Inhibition of protein-protein interactions using designed molecules. 
Chemical Society reviews, 2009; 38: 3289-3300. 
[17] Wilson CGM, Arkin MR, Vassilev L, Fry D eds. Small-Molecule Inhibitors of IL-
2/IL-2R: Lessons Learned and Applied. Springer Berlin Heidelberg: Berlin, 
Heidelberg 2010. 
[18] Higueruelo AP, Schreyer A, Bickerton GR, Pitt WR, Groom CR, Blundell TL. Atomic 
interactions and profile of small molecules disrupting protein-protein interfaces: 
the TIMBAL database. Chem Biol Drug Des, 2009; 74: 457-67. 
[19] Bourgeas R, Basse M-J, Morelli X, Roche P. Atomic analysis of protein-protein 
interfaces with known inhibitors: the 2P2I database. PLoS ONE, 2010; 5: e9598. 
[20] Neugebauer A, Hartmann RW, Klein CD. Prediction of protein-protein interaction 
inhibitors by chemoinformatics and machine learning methods. Journal of 
Medicinal Chemistry, 2007; 50: 4665-4668. 
[21] Morelli X, Bourgeas R, Roche P. Chemical and structural lessons from recent 
successes in protein-protein interaction inhibition (2P2I). Curr Opin Chem Biol, 
2011; 15: 475-81. 
[22] Reynes C, Host H, Camproux AC, Laconde G, Leroux F, Mazars A, Deprez B, 
Fahraeus R, Villoutreix BO, Sperandio O. Designing focused chemical libraries 
enriched in protein-protein interaction inhibitors using machine-learning 
methods. PLoS Comput Biol, 2010; 6: e1000695. 
[23] Sperandio O, Reynes CH, Camproux AC, Villoutreix BO. Rationalizing the chemical 
space of protein-protein interaction inhibitors. Drug Discov Today, 2010; 15: 
220-9. 
[24] Broos K, Trekels M, Jose RA, Demeulemeester J, Vandenbulcke A, Vandeputte N, 
Venken T, Egle B, De Borggraeve WM, Deckmyn H, De Maeyer M. Identification of 
a Small Molecule That Modulates Platelet Glycoprotein Ib-von Willebrand Factor 
Interaction. J Biol Chem, 2012; 287: 9461-72. 
[25] Liu T, Lin Y, Wen X, Jorissen RN, Gilson MK. BindingDB: a web-accessible 
database of experimentally determined protein-ligand binding affinities. Nucleic 
Acids Res, 2007; 35: D198-201. 
[26] Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-
making in medicinal chemistry. Nat Rev Drug Discov, 2007; 6: 881-90. 
 31 
[27] Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and 
computational approaches to estimate solubility and permeability in drug 
discovery and development settings. Advanced drug delivery reviews, 2001; 46: 
3-26. 
[28] Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular 
properties that influence the oral bioavailability of drug candidates. J Med Chem, 
2002; 45: 2615-23. 
[29] Hughes JD, Blagg J, Price DA, Bailey S, Decrescenzo GA, Devraj RV, Ellsworth E, 
Fobian YM, Gibbs ME, Gilles RW, Greene N, Huang E, Krieger-Burke T, Loesel J, 
Wager T, Whiteley L, Zhang Y. Physiochemical drug properties associated with in 
vivo toxicological outcomes. Bioorg Med Chem Lett, 2008; 18: 4872-5. 
[30] Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, 
Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer 
SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, 
O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, 
Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH. An inhibitor 
of Bcl-2 family proteins induces regression of solid tumours. Nature, 2005; 435: 
677-81. 
[31] Kortagere S, Krasowski MD, Ekins S. The importance of discerning shape in 
molecular pharmacology. Trends in pharmacological sciences, 2009; 30: 138-147. 
[32] Akritopoulou-Zanze I, Metz JT, Djuric SW. Topography-biased compound library 
design: the shape of things to come? Drug discovery today, 2007; 12: 948-952. 
[33] Akella LB, DeCaprio D. Cheminformatics approaches to analyze diversity in 
compound screening libraries. Curr Opin Chem Biol, 2010; 14: 325-30. 
[34] Chessari G, Woodhead AJ. From fragment to clinical candidate--a historical 
perspective. Drug Discov Today, 2009; 14: 668-75. 
[35] Reynolds CH, Tounge BA, Bembenek SD. Ligand binding efficiency: trends, 
physical basis, and implications. J Med Chem, 2008; 51: 2432-8. 
[36] Baell JB, Holloway GA. New substructure filters for removal of pan assay 
interference compounds (PAINS) from screening libraries and for their exclusion 
in bioassays. J Med Chem, 2010; 53: 2719-40. 
[37] Lagorce D, Maupetit J, Baell J, Sperandio O, Tuffery P, Miteva MA, Galons H, 
Villoutreix BO. The FAF-Drugs2 server: a multistep engine to prepare electronic 
chemical compound collections. Bioinformatics, 2011; 27: 2018-20. 
[38] Surade S, Blundell TL. Structural biology and drug discovery of difficult targets: 
the limits of ligandability. Chem Biol, 2012; 19: 42-50. 
 
 
